Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)

NCT04255836 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Durvalumab
DRUG: the first line chemotherapy for metastatic NSCLC
RADIATION: stereotactic body radiotherapy (SBRT)

Sponsor

Zhejiang Cancer Hospital